Why have ovarian cancer mortality rates declined? Part II. Case-fatality

Gynecologic Oncology

Volumn 138, Issue 3, 2015, Pages 750-756

  Sopik, Victoria ^a   Iqbal, Javaid ^a   Rosen, Barry ^b   Narod, Steven A ^a,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Mortality; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; OLAPARIB; PACLITAXEL; PLATINUM;

CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER SURGERY; CLINICAL PRACTICE; CYTOREDUCTIVE SURGERY; FATALITY; FEMALE; HUMAN; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; AGE; EARLY DIAGNOSIS; MORTALITY; OVARIAN NEOPLASMS; RISK FACTOR; UNITED STATES;

AGE FACTORS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; OVARIAN NEOPLASMS; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 84941421705     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.06.016     Document Type: Review

References (59)

1. V. Sopik, and et al. Why have ovarian cancer mortality rates declined? Part I. Incidence Gynecol. Oncol. 138 3 2015 741 749
2. J.R. McLaughlin, and et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2 J. Natl. Cancer Inst. 105 2 2013 141 148
3. Howlader N, N.A., Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, CHen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute Bethesda, MD.
4. G. Gigerenzer, and O. Wegwarth Five year survival rates can mislead BMJ 346 2013 f548
5. G.J. Rustin, and et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) Int. J. Gynecol. Cancer 21 2 2011 419 423
6. G.A. Omura, and et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma Cancer 51 5 1983 783 789
7. J.P. Neijt, and et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma Lancet 2 8403 1984 594 600
8. S. Wadler, and et al. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results - Eastern Cooperative Oncology Group Study E2878 Cancer 77 4 1996 733 742
9. J.P. Neijt, and et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer Eur. J. Cancer 27 11 1991 1367 1372
10. R.F. Ozols, and et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 17 2003 3194 3200
11. G.P. Sutton, and et al. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma J. Clin. Oncol. 7 2 1989 223 229
12. Cancer Trends Progress Report - 2011/2012 Update Available from http://progressreport.cancer.gov 2012
13. W.P. McGuire, and et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1 1996 1 6
14. D.S. Chi, and et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm Gynecol. Oncol. 114 1 2009 26 31
15. M.E. van der Burg, and et al. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer Eur. J. Cancer 50 15 2014 2592 2601
16. A. du Bois, and et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 6 2009 1234 1244
17. L.M. Hess, and F.B. Stehman State of the science in ovarian cancer quality of life research: a systematic review Int. J. Gynecol. Cancer 22 7 2012 1273 1280
18. M. Markman Maintenance chemotherapy in the management of epithelial ovarian cancer Cancer Metastasis Rev. 34 1 2015 11 17
19. S.A. Narod Have we given up on a cure for ovarian cancer? A countercurrents series Curr. Oncol. 2015 (in press)
20. E. Pujade-Lauraine, and et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial J. Clin. Oncol. 32 13 2014 1302 1308
21. Oza, A.M., et al., ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Presented at ECC 2013. Abstract LBA6.
22. J. Ledermann, and et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol. 15 8 2014 852 861
23. D.E. Cohn, and et al. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer Gynecol. Oncol. 136 2 2015 293 299
24. A.A. Secord, and et al. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer Int. J. Gynecol. Cancer 23 5 2013 846 852
25. C.T. Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl. Cancer Inst. Monogr. 42 1975 101 104
26. D.S. Chi, and et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) Gynecol. Oncol. 124 1 2012 10 14
27. S.J. Chang, and R.E. Bristow Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease Gynecol. Oncol. 125 2 2012 483 492
28. N.S. Horowitz, and et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 J. Clin. Oncol. 33 8 2015 937 943
29. A.M. Nick, and et al. A framework for a personalized surgical approach to ovarian cancer Nat. Rev. Clin. Oncol. 12 4 2015 239 245
30. A.E. Wahner Hendrickson, and et al. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic Gynecol. Oncol. 137 1 2015 77 85
31. G.D. Aletti, and et al. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon Gynecol. Oncol. 100 1 2006 33 37
32. D.M. Narasimhulu, F. Khoury-Collado, and D.S. Chi Radical surgery in ovarian cancer Curr. Oncol. Rep. 17 4 2015 439
33. R.S. Suidan, and et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer Gynecol. Oncol. 134 3 2014 455 461
34. M.J. Rutten, R. van de Vrie, A. Bruining, A.M. Spijkerboer, B.W. Mol, G.G. Kenter, and M.R. Buist Predicting surgical outcome in patients with international federation of gynecology and obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models Int. J. Gynecol. Cancer 25 3 2015 407 415
35. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol. Oncol. 103 3 2006 1070 1076
36. I. Vergote, and et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N. Engl. J. Med. 363 10 2010 943 953
37. S. Kehoe, and et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial Lancet S0140-6736 14 2015 62223 62226
38. J.D. Wright, and et al. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer 120 8 2014 1246 1254
39. A. Fagotti, and et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience Gynecol. Oncol. 131 2 2013 341 346
40. R.J. Morgan Jr., and et al. Ovarian cancer, version 3.2014 J. Natl. Compr. Cancer Netw. 11 10 2014 1199 1209
41. J.A. Rauh-Hain, and et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma Gynecol. Oncol. 129 1 2013 63 68
42. B. Rosen, and et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer Gynecol. Oncol. 134 3 2014 462 467
43. P.E. Colombo, and et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer Gynecol. Oncol. 135 2 2014 223 230
44. J.A. Lopez, and et al. Clinical pharmacology of intraperitoneal cisplatin Gynecol. Oncol. 20 1 1985 1 9
45. P. Francis, and et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group Pilot Study J. Clin. Oncol. 13 12 1995 2961 2967
46. D.S. Alberts, and et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer Gynecol. Oncol. 103 3 2006 783 792
47. D.K. Armstrong, and et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N. Engl. J. Med. 354 1 2006 34 43
48. L.M. Landrum, and et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study Gynecol. Oncol. 130 1 2013 12 18
49. D. Tewari, and et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 33 13 2015 1460 1466
50. J.L. Walker, and et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study Gynecol. Oncol. 100 1 2006 27 32
51. P. Blinman, and et al. Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study J. Gynecol. Oncol. 24 4 2013 359 366
52. J.N. Barlin, and et al. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer Gynecol. Oncol. 125 3 2012 621 624
53. S. Mulier, and et al. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence Curr. Pharm. Des. 18 25 2012 3793 3803
54. J. Spiliotis, and et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study Ann. Surg. Oncol. 22 5 2015 1570 1575
55. C.W. Helm, and et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry Int. J. Gynecol. Cancer 20 1 2010 61 69
56. E.J. Bowles, and et al. Diffusion of intraperitoneal chemotherapy in women with advanced ovarian cancer in community settings 2003-2008: the effect of the NCI clinical recommendation Front. Oncol. 4 2014 43
57. K.M. Fairfield, and et al. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer Gynecol. Oncol. 134 3 2014 473 477
58. J. Engel, and et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate Eur. J. Cancer 38 18 2002 2435 2445
59. V. Sopik, and et al. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future Gynecol. Oncol. 138 3 2015 757 761